Previous 10 | Next 10 |
Patient in 520 mg/m 2 cohort, previously unresectable, experienced tumor shrinkage and had tumor resected following camsirubicin treatment 3 of 3 patients in the 520 mg/m 2 cohort achieved stable disease WILMETTE, Ill., June 01, 2023 (...
2023-05-31 10:05:20 ET Gainers: Marker Therapeutics ( MRKR ) +34% . Nano-X Imaging ( NNOX ) +13% . Zai Lab ( ZLAB ) +9% . Invivyd ( IVVD ) +8% . Corbus Pharmaceuticals ( CRBP ) +7% . Losers: Belite Bio ( BLTE ) ...
2023-05-11 10:03:26 ET Monopar Therapeutics press release ( NASDAQ: MNPR ): Q1 GAAP EPS of -$0.19 beats by $0.03 . Cash, cash equivalents and shortterm investments as of March 31, 2023, were $11.7 million. For further details see: Monopar Therapeutics G...
WILMETTE, Ill., May 11, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinicalstage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today anno...
2023-03-28 13:10:56 ET Gainers: Biomea Fusion ( BMEA ) +73% . Oscar Health ( OSCR ) +72% . Viking Therapeutics ( VKTX ) +63% . Pyxis Oncology ( PYXS ) +46% . Bird Global ( BRDS ) +44% . NaaS Technology ( NAAS ) +26% ....
2023-03-28 10:00:38 ET Gainers: Biomea Fusion ( BMEA ) +56% . Oscar Health ( OSCR ) +54% . Viking Therapeutics ( VKTX ) +51% . Intra-Cellular Therapies ( ITCI ) +20% . Guardion Health Sciences ( GHSI ) +17% . Losers...
2023-03-28 08:31:04 ET Monopar Therapeutics MNPR -50% as Validive program gets axed after trial failure . WiSA Technologies WISA -28% after proposes securities offering . OncoSec Medical ( ONCS ) -25% . Allarity Therapeutics ALLR -18% amid enr...
WILMETTE, Ill., March 28, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson...
2023-03-28 05:57:36 ET Monopar Therapeutics' ( NASDAQ: MNPR ) is discontinuing the active development of Validive after the drug did not meet the required efficacy to prevent severe oral mucositis (SOM) in patients undergoing chemoradiotherapy (CRT) in a phase 2b/3 trial ca...
WILMETTE, Ill., March 27, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced complet...
News, Short Squeeze, Breakout and More Instantly...
Monopar Therapeutics Inc. Company Name:
MNPR Stock Symbol:
NASDAQ Market:
Monopar Therapeutics Inc. Website:
WILMETTE, Ill., July 09, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the enrollment of the first patient in its first-in-human Phase 1 dosimetry and imaging...
WILMETTE, Ill., June 25, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that its abstract titled “Evaluation of Anti-uPAR Antibody as a Radiopharmaceuti...
Highlights: Builds on Companies’ respective core strengths Aligns intellectual property rights Establishes a long-term supply agreement under which NorthStar provides actinium-225 for Monopar’s development and potential future commercial programs WILMETTE, ...